Boothbay Fund Management LLC Sells 104,807 Shares of Establishment Labs Holdings Inc. $ESTA

Boothbay Fund Management LLC reduced its position in Establishment Labs Holdings Inc. (NASDAQ:ESTA) by 19.5% during the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 432,706 shares of the company’s stock after selling 104,807 shares during the quarter. Boothbay Fund Management LLC owned 1.49% of Establishment Labs worth $17,737,000 as of its most recent SEC filing.

Other institutional investors have also added to or reduced their stakes in the company. Tyro Capital Management LLC grew its stake in shares of Establishment Labs by 1.0% during the third quarter. Tyro Capital Management LLC now owns 1,077,456 shares of the company’s stock valued at $44,165,000 after buying an additional 10,735 shares during the last quarter. William Blair Investment Management LLC lifted its stake in shares of Establishment Labs by 17.6% during the 3rd quarter. William Blair Investment Management LLC now owns 1,017,543 shares of the company’s stock worth $41,709,000 after acquiring an additional 152,299 shares during the last quarter. Bamco Inc. NY boosted its holdings in Establishment Labs by 21.5% during the 2nd quarter. Bamco Inc. NY now owns 907,537 shares of the company’s stock valued at $38,761,000 after acquiring an additional 160,755 shares during the period. Mudita Advisors LLP boosted its holdings in Establishment Labs by 14.3% during the 3rd quarter. Mudita Advisors LLP now owns 686,764 shares of the company’s stock valued at $28,150,000 after acquiring an additional 86,100 shares during the period. Finally, Balyasny Asset Management L.P. grew its position in Establishment Labs by 50.9% in the 2nd quarter. Balyasny Asset Management L.P. now owns 488,688 shares of the company’s stock valued at $20,872,000 after acquiring an additional 164,788 shares during the last quarter. Institutional investors own 72.91% of the company’s stock.

Establishment Labs Price Performance

ESTA opened at $63.35 on Friday. The company has a market capitalization of $1.86 billion, a price-to-earnings ratio of -36.41 and a beta of 0.91. The company has a current ratio of 3.04, a quick ratio of 2.00 and a debt-to-equity ratio of 10.51. Establishment Labs Holdings Inc. has a 12-month low of $26.56 and a 12-month high of $83.31. The business’s fifty day simple moving average is $70.25 and its 200-day simple moving average is $60.54.

Establishment Labs (NASDAQ:ESTA) last released its quarterly earnings data on Tuesday, February 24th. The company reported ($0.09) earnings per share for the quarter, beating the consensus estimate of ($0.22) by $0.13. Establishment Labs had a negative return on equity of 201.79% and a negative net margin of 24.19%.The firm had revenue of $64.62 million during the quarter, compared to the consensus estimate of $63.80 million. During the same period in the previous year, the company posted ($1.19) earnings per share. The firm’s quarterly revenue was up 45.2% on a year-over-year basis. On average, equities research analysts anticipate that Establishment Labs Holdings Inc. will post -2.41 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of analysts have weighed in on ESTA shares. Wall Street Zen upgraded Establishment Labs from a “hold” rating to a “buy” rating in a research note on Saturday, March 7th. Citigroup cut their price target on shares of Establishment Labs from $81.00 to $74.00 and set a “neutral” rating on the stock in a report on Wednesday. Canaccord Genuity Group raised their price target on shares of Establishment Labs from $85.00 to $90.00 and gave the stock a “buy” rating in a research note on Thursday, February 26th. Needham & Company LLC lifted their price objective on shares of Establishment Labs from $84.00 to $86.00 and gave the company a “buy” rating in a report on Tuesday, February 24th. Finally, Mizuho boosted their price objective on shares of Establishment Labs from $90.00 to $100.00 and gave the company an “outperform” rating in a research report on Wednesday, February 25th. Six equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, Establishment Labs presently has a consensus rating of “Moderate Buy” and an average target price of $86.86.

About Establishment Labs

Establishment Labs Holdings Inc is a global medical technology company specializing in the design, development and manufacture of silicone gel breast implants for aesthetic and reconstructive surgery. The company’s proprietary portfolio is built around patient-focused safety, customization and innovation, offering solutions intended to enhance surgical outcomes and support clinical traceability.

The company’s flagship products fall under the Motiva® brand, which includes a range of ergonomic and round breast implants featuring SilkSurface® texturing and an embedded Q Inside® Safety microtransponder for unique implant identification.